Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 24


The cross-talk of HIV-1 Tat and methamphetamine in HIV-associated neurocognitive disorders.

Mediouni S, Garibaldi Marcondes MC, Miller C, McLaughlin JP, Valente ST.

Front Microbiol. 2015 Oct 23;6:1164. doi: 10.3389/fmicb.2015.01164. eCollection 2015. Review.


The opioid receptors as targets for drug abuse medication.

Noble F, Lenoir M, Marie N.

Br J Pharmacol. 2015 Aug;172(16):3964-79. doi: 10.1111/bph.13190. Epub 2015 Jun 26.


The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study.

Ray LA, Bujarski S, Courtney KE, Moallem NR, Lunny K, Roche D, Leventhal AM, Shoptaw S, Heinzerling K, London ED, Miotto K.

Neuropsychopharmacology. 2015 Sep;40(10):2347-56. doi: 10.1038/npp.2015.83. Epub 2015 Mar 24.


Impact of prospectively determined A118G polymorphism on treatment response to injectable naltrexone among methamphetamine-dependent patients: an open-label, pilot study.

Pal R, Mendelson JE, Flower K, Garrison K, Yount G, Coyle JR, Galloway GP.

J Addict Med. 2015 Mar-Apr;9(2):130-5. doi: 10.1097/ADM.0000000000000107.


Naltrexone and bupropion, alone or combined, do not alter the reinforcing effects of intranasal methamphetamine.

Stoops WW, Pike E, Hays LR, Glaser PE, Rush CR.

Pharmacol Biochem Behav. 2015 Feb;129:45-50. doi: 10.1016/j.pbb.2014.11.018. Epub 2014 Nov 29.


Naloxone induces frequent jumping after chronic morphine and methamphetamine co-administration in rats.

Kaka G, Rahmanzade R, Safee F, Haghparast A.

Basic Clin Neurosci. 2014 Winter;5(1):42-7.


Psychostimulant addiction treatment.

Phillips KA, Epstein DH, Preston KL.

Neuropharmacology. 2014 Dec;87:150-60. doi: 10.1016/j.neuropharm.2014.04.002. Epub 2014 Apr 12. Review.


Nanoscale effects of ethanol and naltrexone on protein organization in the plasma membrane studied by photoactivated localization microscopy (PALM).

Tobin SJ, Cacao EE, Hong DW, Terenius L, Vukojevic V, Jovanovic-Talisman T.

PLoS One. 2014 Feb 4;9(2):e87225. doi: 10.1371/journal.pone.0087225. eCollection 2014.


Separate and combined impact of acute naltrexone and alprazolam on subjective and physiological effects of oral d-amphetamine in stimulant users.

Marks KR, Lile JA, Stoops WW, Rush CR.

Psychopharmacology (Berl). 2014 Jul;231(14):2741-50. doi: 10.1007/s00213-014-3449-x. Epub 2014 Jan 25.


Morphine intake and the effects of naltrexone and buprenorphine on the acquisition of methamphetamine intake.

Eastwood EC, Phillips TJ.

Genes Brain Behav. 2014 Feb;13(2):226-35. doi: 10.1111/gbb.12100. Epub 2013 Nov 18.


Pharmacotherapy for stimulant-related disorders.

Haile CN, Kosten TR.

Curr Psychiatry Rep. 2013 Nov;15(11):415. doi: 10.1007/s11920-013-0415-y. Review.


Effects of acute oral naltrexone on the subjective and physiological effects of oral D-amphetamine and smoked cocaine in cocaine abusers.

Comer SD, Mogali S, Saccone PA, Askalsky P, Martinez D, Walker EA, Jones JD, Vosburg SK, Cooper ZD, Roux P, Sullivan MA, Manubay JM, Rubin E, Pines A, Berkower EL, Haney M, Foltin RW.

Neuropsychopharmacology. 2013 Nov;38(12):2427-38. doi: 10.1038/npp.2013.143. Epub 2013 Jun 5.


Attenuation of cocaine and heroin seeking by μ-opioid receptor antagonism.

Giuliano C, Robbins TW, Wille DR, Bullmore ET, Everitt BJ.

Psychopharmacology (Berl). 2013 May;227(1):137-47. doi: 10.1007/s00213-012-2949-9. Epub 2013 Jan 9.


The detrimental effects of emotional process dysregulation on decision-making in substance dependence.

Murphy A, Taylor E, Elliott R.

Front Integr Neurosci. 2012 Nov 7;6:101. doi: 10.3389/fnint.2012.00101. eCollection 2012.


Effects of amphetamine on the human brain opioid system--a positron emission tomography study.

Guterstam J, Jayaram-Lindström N, Cervenka S, Frost JJ, Farde L, Halldin C, Franck J.

Int J Neuropsychopharmacol. 2013 May;16(4):763-9. doi: 10.1017/S1461145712000818. Epub 2012 Aug 29.


The genetics of the opioid system and specific drug addictions.

Levran O, Yuferov V, Kreek MJ.

Hum Genet. 2012 Jun;131(6):823-42. doi: 10.1007/s00439-012-1172-4. Epub 2012 May 1. Review.


Methylphenidate and μ opioid receptor interactions: a pharmacological target for prevention of stimulant abuse.

Zhu J, Spencer TJ, Liu-Chen LY, Biederman J, Bhide PG.

Neuropharmacology. 2011 Jul-Aug;61(1-2):283-92. doi: 10.1016/j.neuropharm.2011.04.015. Epub 2011 Apr 23.


Naltrexone decreases D-amphetamine and ethanol self-administration in rhesus monkeys.

Jimenez-Gomez C, Winger G, Dean RL, Deaver DR, Woods JH.

Behav Pharmacol. 2011 Feb;22(1):87-90. doi: 10.1097/FBP.0b013e3283423d55.


OPRM1 gene variants modulate amphetamine-induced euphoria in humans.

Dlugos AM, Hamidovic A, Hodgkinson C, Shen PH, Goldman D, Palmer AA, de Wit H.

Genes Brain Behav. 2011 Mar;10(2):199-209. doi: 10.1111/j.1601-183X.2010.00655.x. Epub 2010 Nov 2.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk